ReviewBMJ global health2020
'Dark matter', second waves and epidemiological modelling.
Review in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- The Free Energy Principle and Free Markets.Entropy (Basel, Switzerland) · 2026Article
- A scalable variational method for estimating the latent infection-rate field of an outbreak.PloS one · 2026Article
- Dynamic causal models in infectious disease epidemiology-an assessment of their predictive validity based on the COVID-19 epidemic in the UK 2020 to 2024.Frontiers in public health · 2025Article
- Estimating the value of face coverings during the COVID-19 epidemic: a dynamic causal modelling study.BMJ public health · 2025Article
- What Lessons can Be Learned From the Management of the COVID-19 Pandemic?International journal of public health · 2025Review
- A follow up report validating long term predictions of the COVID-19 epidemic in the UK using a dynamic causal model.Frontiers in public health · 2024Article
- Article
- Inferring Trajectories of Psychotic Disorders Using Dynamic Causal Modeling.Computational psychiatry (Cambridge, Mass.) · 2023Article
- Precision Public Health and Structural Racism in the United States: Promoting Health Equity in the COVID-19 Pandemic Response.JMIR public health and surveillance · 2022Article
- The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2.Trends in molecular medicine · 2021Review
- Effect estimates of COVID-19 non-pharmaceutical interventions are non-robust and highly model-dependent.Journal of clinical epidemiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Recent reports using conventional Susceptible, Exposed, Infected and Removed models suggest that the next wave of the COVID-19 pandemic in the UK could overwhelm health services, with fatalities exceeding the first wave. We used Bayesian model comparison to revisit these conclusions, allowing for heterogeneity of exposure, susceptibility and transmission. We used dynamic causal modelling to estimate the evidence for alternative models of daily cases and deaths from the USA, the UK, Brazil, Italy, France, Spain, Mexico, Belgium, Germany and Canada over the period 25 January 2020 to 15 June 2020. These data were used to estimate the proportions of people (i) not exposed to the virus, (ii) not susceptible to infection when exposed and (iii) not infectious when susceptible to infection. Bayesian model comparison furnished overwhelming evidence for heterogeneity of exposure, susceptibility and transmission. Furthermore, both lockdown and the build-up of population immunity contributed to viral transmission in all but one country. Small variations in heterogeneity were sufficient to explain large differences in mortality rates. The best model of UK data predicts a second surge of fatalities will be much less than the first peak. The size of the second wave depends sensitively on the loss of immunity and the efficacy of Find-Test-Trace-Isolate-Support programmes. In summary, accounting for heterogeneity of exposure, susceptibility and transmission suggests that the next wave of the SARS-CoV-2 pandemic will be much smaller than conventional models predict, with less economic and health disruption. This heterogeneity means that seroprevalence underestimates effective herd immunity and, crucially, the potential of public health programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.